Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.42
+0.130010.08%
Post-market: 1.430.0100+0.70%19:25 EDT
Volume:3.48M
Turnover:4.93M
Market Cap:310.60M
PE:-1.16
High:1.47
Open:1.30
Low:1.29
Close:1.29
Loading ...
Mar 14, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Feb 23, 2024

Correspondence

Form CORRESP - Correspondence
Feb 16, 2024

Major Issues Report

Form 8-K - Current report
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 31, 2024

Major Issues Report

Form 8-K - Current report
Jan 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 05, 2024

Major Issues Report

Form 8-K - Current report
Dec 20, 2023

Major Issues Report

Form 8-K - Current report
Dec 19, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 16, 2023

Correspondence

Form CORRESP - Correspondence
Nov 03, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 02, 2023

Major Issues Report

Form 8-K - Current report
Oct 26, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Oct 18, 2023

Major Issues Report

Form 8-K/A - Current report: [Amend]
Oct 16, 2023

Major Issues Report

Form 8-K - Current report
Aug 07, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 02, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 02, 2023

Major Issues Report

Form 8-K - Current report